La cadena de opciones muestra datos clave de las opciones de acciones de Agios Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Agios Pharmaceuticals..

Agios Pharmaceuticals (NASDAQ:AGIO) Bolsa, Cadena de Opciones

Agios Pharmaceuticals

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals Inc

News

AGIO

Agios Reveals Anticipated Key 2025 Milestones And Value-driving Catalysts Through 2026

The review classification for this application is Standard and the Prescription Drug User Fee Act (PDUFA) goal date is September 7, 2025.

Agios Pharmaceuticals Says FDA Accepted sNDA For PYRUKYND (Mitapivat) For Treatment Of Adult Patients With Non-Transfusion-Dependent And Transfusion-Dependent Alpha- Or Beta-thalassemia

Agios Pharmaceuticals Filing Reported FDA Approved Update To PYRUKYND For Hemolytic Anemia In Adults With Pyruvate Kinase Deficiency; US Prescribing Info Revised To Include Liver Injury Risk

Cantor Fitzgerald analyst Eric Schmidt reiterates Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) from Overweight to Overweight.

Reiteration

Analyst Ratings

Cantor Fitzgerald Reiterates Overweight on Agios Pharmaceuticalsto Overweight

. Earlier, in November 2020, the U.S. Food and Drug Administration (FDA) also granted orphan drug designation to mitapivat for sickle cell disease.

Biotech

Health Care

General

The European Commission Has Adopted A Positive Decision For The Designation Of Agios Pharmaceuticals' Mitapivat As An Orphan Medicinal Product For Sickle Cell Disease

U.S. stocks were mostly higher, with the Nasdaq Composite gaining around 1% on Monday.
Shares of Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose sharply during Monday's session after Wedbush maintained an Outperform rating on the stock and raised its price target <a href="https://www.benzinga.com/markets/equities/24/12/42505310/tesla-prepares-for-holiday-rush-tapping-into-global-supercharger-demand-to-drive-revenue-growth">from $400 to $515</a>.
Tesla shares gained 5% to $458.08 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) shares gained 59.6% to $1.5000.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) shares jumped 42.4% to $9.49.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) climbed 31.8% to $2.6950.</li>
<li>Viridian Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>) gained 31.8% to $23.53 after the company announced Phase 3 results for its thyroid eye disease treatment trial.</li>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) rose 25.5% to $8.99.</li>
<li>Edgewise Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) gained 24.7% to $34.45 after the company reported topline results from its Phase 2 CANYON trial of Sevasemten in individuals with Becker muscular dystrophy, with the trial meeting its primary endpoint.</li>
<li>Aehr Test Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHR#NASDAQ">AEHR</a>) rose 24.2% to $14.32 after the company announced it secured a $10 million order for AI semiconductor testing.</li>
<li>Bitdeer Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) climbed 19.8% to $25.08. Shares of Bitcoin miners and crypto-linked stocks traded higher after Bitcoin reached an all-time high.</li>
<li>Cipher Mining Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) gained 18.4% to $7.26. Shares of Bitcoin miners and crypto-linked stocks traded higher after Bitcoin reached an all-time high.</li>
<li>TeraWulf Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) rose 15.5% to $8.14. Shares of Bitcoin miners and crypto-linked stocks traded higher after Bitcoin reached an all-time high.</li>
<li>Hut 8 Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) gained 13.4% to $30.99. Shares of Bitcoin miners and crypto-linked stocks traded higher after Bitcoin reached an all-time high.</li>
<li>MARA Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) gained 10.5% to $25.11. Shares of Bitcoin miners and crypto-linked stocks traded higher after Bitcoin reached an all-time high.</li>
<li>Asana, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NASDAQ">ASAN</a>) gained 9.5% to $26.45.</li>
<li>Agios Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) surged 9.1% to $42.54.</li>
<li>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) surged 7.6% to $242.06 on continued momentum from last week after the company reported earnings for the fourth-quarter.</li>
<li>Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) gained 7% to $109.62.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42507587/tesla-to-rally-around-18-here-are-10-top-analyst-forecasts-for-monday">Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday</a></li>
</ul>

Intraday Update

Markets

Movers

AEHR

ASAN

AVGO

BTDR

CIFR

EWTX

MARA

QUBT

RGTI

SGMO

TSLA

VRDN

WULF

Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday

8 analysts have shared their evaluations of Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $56.62, a high estimate of $75.00, and a low estimate of $51.00. This current average reflects an increase of 3.26% from the previous average price target of $54.83. 
<img src="https://www.benzinga.com/files/images/story/2024/1733850120_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Agios Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$57.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$75.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$53.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$51.00</td>
<td>-</td>
</tr>
<tr>
<td>Danielle Brill</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$51.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Berens</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$56.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Agios Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Agios Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Agios Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Agios Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AGIO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Agios Pharmaceuticals analyst ratings.</a>
<h2>About Agios Pharmaceuticals</h2>
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
<h3>Key Indicators: Agios Pharmaceuticals's Financial Health</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Agios Pharmaceuticals displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 21.15%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 10574.69%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 82.89%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Agios Pharmaceuticals's ROA excels beyond industry benchmarks, reaching 73.92%. This signifies efficient management of assets and strong financial health.
Debt Management: Agios Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.04, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Agios Pharmaceuticals

RBC Capital analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Outperform and raises the price target from $55 to $57.

Price Target

RBC Capital Maintains Outperform on Agios Pharmaceuticals, Raises Price Target to $57

Scotiabank analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Sector Outperform and raises the price target from $53 to $75.

Scotiabank Maintains Sector Outperform on Agios Pharmaceuticals, Raises Price Target to $75

Agios Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today presented positive results from the Phase 3 ENERGIZE-T study investigating mitapivat, an oral, small molecule PK activator, in adults with transfusion-dependent alpha- or beta-thalassemia. These findings were shared in an oral presentation (abstract #409) at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California.
In the ENERGIZE-T trial, mitapivat demonstrated a statistically significant reduction in transfusion burden compared to placebo in patients with transfusion-dependent alpha- or beta-thalassemia, achieving its primary endpoint. Additionally, the ENERGIZE-T study met all the key secondary endpoints, with mitapivat demonstrating a statistically significant reduction in additional measures of transfusion reduction response compared to placebo. In June 2024, Agios also <a href="https://www.globenewswire.com/Tracker?data=yCZIHDR8PSvrAcYmrbhYVzXtz0qOrlBEmNLt7nN_xw6pl1Mj2AXdoy1h6DGsnSHtC9uUFdnfS-kmUwx8-iSnaOJkdU3hjhRmj1SJM6ZrLFO6iwRjg8fcimCj7_cSLjAcTUnWPq0clc5THhnffh8TSuew3ZJSODjBe9FO6EN8DPbro4Y_f9jLQwMPuUlNC79JIOX2IXMP3L7atf5mK8ExdWvum1h8-Fgpguku085aOMQ=">presented positive results</a> from the Phase 3 ENERGIZE study, which evaluated mitapivat in adults with non-transfusion-dependent alpha- or beta-thalassemia.

Agios Presented At ASH, Results From Phase 3 ENERGIZE-T Study of Mitapivat; Study Achieved Primary, All Key Secondary Endpoints In Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia

Agios Pharmaceuticals Announced It Will Present New Data And Results From Its Phase 3 Study On AG-946 At The 66th American Society Of Hematology Annual Meeting In San Diego, California From December 7-10, 2024

6 analysts have shared their evaluations of Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $53.5, with a high estimate of $56.00 and a low estimate of $51.00. This current average represents a 3.17% decrease from the previous average price target of $55.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1730487646_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Alnylam Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$53.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$51.00</td>
<td>-</td>
</tr>
<tr>
<td>Danielle Brill</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$51.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Berens</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$56.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Alnylam Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Alnylam Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Alnylam Pharmaceuticals's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AGIO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Alnylam Pharmaceuticals analyst ratings.</a>
<h2>All You Need to Know About Alnylam Pharmaceuticals</h2>
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
<h3>Unraveling the Financial Story of Alnylam Pharmaceuticals</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Alnylam Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 28.35% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Alnylam Pharmaceuticals's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -1115.71%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Alnylam Pharmaceuticals's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -13.69%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -11.85%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.1.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)

RBC Capital analyst Gregory Renza reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Outperform and maintains $55 price target.

RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $55 Price Target

Scotiabank analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Sector Outperform and raises the price target from $51 to $53.

Scotiabank Maintains Sector Outperform on Agios Pharmaceuticals, Raises Price Target to $53

WIIM

Agios Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 revenue results.

Guidance

Agios Expects Cash And Equivalents, Together With Anticipated Product Revenue And Interest Income, To Provide Financial Independence To Prepare For Potential PYRUKYND Launches, Advance Existing Programs, And Expand Pipeline

Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) reported quarterly sales of $8.96 million which missed the analyst consensus estimate of $9.46 million by 5.25 percent. This is a 21.15 percent increase over sales of $7.40 million the same period last year.

Earnings

Earnings Misses

Agios Pharmaceuticals Q3 Sales $8.96M Miss $9.46M Estimate

Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) will release its quarterly earnings report on Thursday, 2024-10-31. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Agios Pharmaceuticals to report an earnings per share (EPS) of $-1.01.
Anticipation surrounds Agios Pharmaceuticals's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
Last quarter the company missed EPS by $0.10, which was followed by a 1.21% drop in the share price the next day.
Here's a look at Agios Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.59</td>
<td>-1.65</td>
<td>-1.65</td>
<td>-1.70</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.69</td>
<td>-1.45</td>
<td>-1.72</td>
<td>-1.64</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-0.0%</td>
<td>-1.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730297000_0.png" alt="eps graph" />
<h3>Analysts' Perspectives on Agios Pharmaceuticals</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Agios Pharmaceuticals.
Analysts have given Agios Pharmaceuticals a total of 5 ratings, with the consensus rating being Outperform. The average one-year price target is $53.6, indicating a potential 14.46% upside.
<h3>Analyzing Ratings Among Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Veracyte, Catalyst Pharmaceuticals and Geron, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>For Veracyte, analysts project an Buy trajectory, with an average 1-year price target of $36.17, indicating a potential 22.76% downside.</li>
<li>The consensus outlook from analysts is an Buy trajectory for Catalyst Pharmaceuticals, with an average 1-year price target of $30.33, indicating a potential 35.23% downside.</li>
<li>Geron is maintaining an Outperform status according to analysts, with an average 1-year price target of $6.33, indicating a potential 86.48% downside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Veracyte, Catalyst Pharmaceuticals and Geron, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agios Pharmaceuticals</td>
<td>Outperform</td>
<td>28.35%</td>
<td>$7.12M</td>
<td>-13.69%</td>
</tr>
<tr>
<td>Veracyte</td>
<td>Buy</td>
<td>26.69%</td>
<td>$77.91M</td>
<td>0.51%</td>
</tr>
<tr>
<td>Catalyst Pharmaceuticals</td>
<td>Buy</td>
<td>23.23%</td>
<td>$107.31M</td>
<td>6.97%</td>
</tr>
<tr>
<td>Geron</td>
<td>Outperform</td>
<td>2941.38%</td>
<td>$865K</td>
<td>-20.68%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Agios Pharmaceuticals ranks at the bottom for Revenue Growth among its peers. It also ranks at the bottom for Gross Profit. For Return on Equity, it is at the bottom.
<h3>About Agios Pharmaceuticals</h3>
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
<h3>Financial Insights: Agios Pharmaceuticals</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Agios Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 28.35% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Agios Pharmaceuticals's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -1115.71%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -13.69%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -11.85%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Agios Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/AGIO/earnings">To track all earnings releases for Agios Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Agios Pharmaceuticals

Agios Completes Enrollment In Phase 3 RISE UP Study Of Mitapivat For Sickle Cell Disease

Scotiabank analyst Greg Harrison initiates coverage on Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Sector Outperform rating and announces Price Target of $51.

Initiation

Scotiabank Initiates Coverage On Agios Pharmaceuticals with Sector Outperform Rating, Announces Price Target of $51

Scotiabank raised the firm's price target on Agios Pharmaceuticals (AGIO) to $75 from $53 and keeps an Outperform rating on the shares. The firm in...

Agios Pharmaceuticals price target raised to $75 from $53 at Scotiabank

In a report released yesterday, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Agios Pharma (AGIO – Research Report), wi...

Agios Pharma's Competitive Edge and Strong Efficacy Data Bolster Buy Rating

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Agios Pharmaceuticals (AGIO) announced that the European Commission, EC, has adopted a positive decision for the designation of mitapivat, an oral,...

Agios Pharmaceuticals announces EC adopted positive decision for mitapivat

The best U.S. value stocks by Quant: AGIO, DLX, PPC

Agios Pharmaceuticals (AGIO) announced that the U.S. Food and Drug Administration, FDA, accepted the company's supplemental New Drug Application, s...

Agios Pharmaceuticals announces FDA accepted sNDA for PYRUKYND

Agios' supplemental new drug application for its thalassemia treatment gets FDA nod

Leerink Partners analyst Andrew Berens maintained a Hold rating on Agios Pharma (AGIO – Research Report) on January 6. The company's shares closed ...

Leerink Partners Remains a Hold on Agios Pharma (AGIO)

RBC Capital analyst Gregory Renza maintained a Buy rating on Agios Pharma (AGIO – Research Report) on January 7 and set a price target of $57.00. T...

RBC Capital Sticks to Its Buy Rating for Agios Pharma (AGIO)

Agios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA Decision

CMRX

HRMY

IPHA

IPHYF

LAUR

MCRB

SKYW

ULCC

UNFI

Press Releases

Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024

Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

Agios Reports Business Highlights and Third Quarter 2024 Financial Results

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition

Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease

Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

Legal

FDA Accepts Agios' Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia

Comments

Agios Pharmaceuticals

Agios Pharmaceuticals (AGIO) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL